195 related articles for article (PubMed ID: 38775157)
1. BET inhibition reforms the immune microenvironment and alleviates T cell dysfunction in chronic lymphocytic leukemia.
Smith AL; Skupa SA; Eiken AP; Reznicek TE; Schmitz E; Williams N; Moore DY; D'Angelo CR; Kallam A; Lunning MA; Bociek RG; Vose JM; Mohamed E; Mahr AR; Denton PW; Powell B; Bollag G; Rowley MJ; El-Gamal D
JCI Insight; 2024 May; 9(10):. PubMed ID: 38775157
[TBL] [Abstract][Full Text] [Related]
2. HDAC6 Inhibition Alleviates CLL-Induced T-Cell Dysfunction and Enhances Immune Checkpoint Blockade Efficacy in the Eμ-TCL1 Model.
Maharaj K; Powers JJ; Mediavilla-Varela M; Achille A; Gamal W; Quayle S; Jones SS; Sahakian E; Pinilla-Ibarz J
Front Immunol; 2020; 11():590072. PubMed ID: 33329575
[TBL] [Abstract][Full Text] [Related]
3. BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia.
Kong W; Dimitri A; Wang W; Jung IY; Ott CJ; Fasolino M; Wang Y; Kulikovskaya I; Gupta M; Yoder T; DeNizio JE; Everett JK; Williams EF; Xu J; Scholler J; Reich TJ; Bhoj VG; Haines KM; Maus MV; Melenhorst JJ; Young RM; Jadlowsky JK; Marcucci KT; Bradner JE; Levine BL; Porter DL; Bushman FD; Kohli RM; June CH; Davis MM; Lacey SF; Vahedi G; Fraietta JA
J Clin Invest; 2021 Aug; 131(16):. PubMed ID: 34396987
[TBL] [Abstract][Full Text] [Related]
4. Expanded antigen-experienced CD160
Bozorgmehr N; Okoye I; Oyegbami O; Xu L; Fontaine A; Cox-Kennett N; Larratt LM; Hnatiuk M; Fagarasanu A; Brandwein J; Peters AC; Elahi S
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33931471
[TBL] [Abstract][Full Text] [Related]
5. Leukemic cell-secreted interleukin-9 suppresses cytotoxic T cell-mediated killing in chronic lymphocytic leukemia.
Boncompagni G; Tatangelo V; Lopresti L; Ulivieri C; Capitani N; Tangredi C; Finetti F; Marotta G; Frezzato F; Visentin A; Ciofini S; Gozzetti A; Bocchia M; Calzada-Fraile D; Martin Cofreces NB; Trentin L; Patrussi L; Baldari CT
Cell Death Dis; 2024 Feb; 15(2):144. PubMed ID: 38360867
[TBL] [Abstract][Full Text] [Related]
6. BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor.
Ozer HG; El-Gamal D; Powell B; Hing ZA; Blachly JS; Harrington B; Mitchell S; Grieselhuber NR; Williams K; Lai TH; Alinari L; Baiocchi RA; Brinton L; Baskin E; Cannon M; Beaver L; Goettl VM; Lucas DM; Woyach JA; Sampath D; Lehman AM; Yu L; Zhang J; Ma Y; Zhang Y; Spevak W; Shi S; Severson P; Shellooe R; Carias H; Tsang G; Dong K; Ewing T; Marimuthu A; Tantoy C; Walters J; Sanftner L; Rezaei H; Nespi M; Matusow B; Habets G; Ibrahim P; Zhang C; Mathé EA; Bollag G; Byrd JC; Lapalombella R
Cancer Discov; 2018 Apr; 8(4):458-477. PubMed ID: 29386193
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-10 suppression enhances T-cell antitumor immunity and responses to checkpoint blockade in chronic lymphocytic leukemia.
Rivas JR; Liu Y; Alhakeem SS; Eckenrode JM; Marti F; Collard JP; Zhang Y; Shaaban KA; Muthusamy N; Hildebrandt GC; Fleischman RA; Chen L; Thorson JS; Leggas M; Bondada S
Leukemia; 2021 Nov; 35(11):3188-3200. PubMed ID: 33731852
[TBL] [Abstract][Full Text] [Related]
8. T Cells in Chronic Lymphocytic Leukemia: A Two-Edged Sword.
Vlachonikola E; Stamatopoulos K; Chatzidimitriou A
Front Immunol; 2020; 11():612244. PubMed ID: 33552073
[TBL] [Abstract][Full Text] [Related]
9. Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects.
Eiken AP; Smith AL; Skupa SA; Schmitz E; Rana S; Singh S; Kumar S; Mallareddy JR; de Cubas AA; Krishna A; Kalluchi A; Rowley MJ; D'Angelo CR; Lunning MA; Bociek RG; Vose JM; Natarajan A; El-Gamal D
Cancer Res Commun; 2024 May; 4(5):1328-1343. PubMed ID: 38687198
[TBL] [Abstract][Full Text] [Related]
10. CD84 regulates PD-1/PD-L1 expression and function in chronic lymphocytic leukemia.
Lewinsky H; Barak AF; Huber V; Kramer MP; Radomir L; Sever L; Orr I; Mirkin V; Dezorella N; Shapiro M; Cohen Y; Shvidel L; Seiffert M; Herishanu Y; Becker-Herman S; Shachar I
J Clin Invest; 2018 Dec; 128(12):5465-5478. PubMed ID: 30277471
[TBL] [Abstract][Full Text] [Related]
11. The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment.
Kim E; Ten Hacken E; Sivina M; Clarke A; Thompson PA; Jain N; Ferrajoli A; Estrov Z; Keating MJ; Wierda WG; Bhalla KN; Burger JA
Leukemia; 2020 Jun; 34(6):1588-1598. PubMed ID: 31862959
[TBL] [Abstract][Full Text] [Related]
12. Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia.
Tettamanti S; Rotiroti MC; Giordano Attianese GMP; Arcangeli S; Zhang R; Banerjee P; Galletti G; McManus S; Mazza M; Nicolini F; Martinelli G; Ivan C; Veliz Rodriguez T; Barbaglio F; Scarfò L; Ponzoni M; Wierda W; Gandhi V; Keating M; Biondi A; Caligaris-Cappio F; Biagi E; Ghia P; Bertilaccio MTS
Leuk Lymphoma; 2022 Jul; 63(7):1566-1579. PubMed ID: 35259043
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Eµ-TCL1 CLL mouse model.
McClanahan F; Riches JC; Miller S; Day WP; Kotsiou E; Neuberg D; Croce CM; Capasso M; Gribben JG
Blood; 2015 Jul; 126(2):212-21. PubMed ID: 25979947
[TBL] [Abstract][Full Text] [Related]
14. Control of PD-L1 expression in CLL-cells by stromal triggering of the Notch-c-Myc-EZH2 oncogenic signaling axis.
Böttcher M; Bruns H; Völkl S; Lu J; Chartomatsidou E; Papakonstantinou N; Mentz K; Büttner-Herold M; Zenz T; Herling M; Huber W; Ghia P; Stamatopoulos K; Mackensen A; Mougiakakos D
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33931470
[TBL] [Abstract][Full Text] [Related]
15. Chronic lymphocytic leukemia cells express CD38 in response to Th1 cell-derived IFN-γ by a T-bet-dependent mechanism.
Bürgler S; Gimeno A; Parente-Ribes A; Wang D; Os A; Devereux S; Jebsen P; Bogen B; Tjønnfjord GE; Munthe LA
J Immunol; 2015 Jan; 194(2):827-35. PubMed ID: 25505279
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia.
McClanahan F; Hanna B; Miller S; Clear AJ; Lichter P; Gribben JG; Seiffert M
Blood; 2015 Jul; 126(2):203-11. PubMed ID: 25800048
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-10 receptor signaling promotes the maintenance of a PD-1
Hanna BS; Llaó-Cid L; Iskar M; Roessner PM; Klett LC; Wong JKL; Paul Y; Ioannou N; Öztürk S; Mack N; Kalter V; Colomer D; Campo E; Bloehdorn J; Stilgenbauer S; Dietrich S; Schmidt M; Gabriel R; Rippe K; Feuerer M; Ramsay AG; Lichter P; Zapatka M; Seiffert M
Immunity; 2021 Dec; 54(12):2825-2841.e10. PubMed ID: 34879221
[TBL] [Abstract][Full Text] [Related]
18. Idelalisib and caffeine reduce suppression of T cell responses mediated by activated chronic lymphocytic leukemia cells.
Hock BD; MacPherson SA; McKenzie JL
PLoS One; 2017; 12(3):e0172858. PubMed ID: 28257435
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic repolarization of T lymphocytes from chronic lymphocytic leukemia patients using 5-aza-2'-deoxycytidine.
Dubovsky JA; Powers JJ; Gao Y; Mariusso LF; Sotomayor EM; Pinilla-Ibarz JA
Leuk Res; 2011 Sep; 35(9):1193-9. PubMed ID: 21377729
[TBL] [Abstract][Full Text] [Related]
20. Chronic Lymphocytic Leukemia-Derived IL-10 Suppresses Antitumor Immunity.
Alhakeem SS; McKenna MK; Oben KZ; Noothi SK; Rivas JR; Hildebrandt GC; Fleischman RA; Rangnekar VM; Muthusamy N; Bondada S
J Immunol; 2018 Jun; 200(12):4180-4189. PubMed ID: 29712773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
